About Hyaluronidase-2
Hyaluronidase-2 (HYAL2) is a protein
from Homo sapiens identified by UniProt accession
Q12891, 473 residues long.
MolForge cross-references it against 0 known binders and
177 disease associations.
Target properties
| Protein name | Hyaluronidase-2 |
|---|
| UniProt accession | Q12891 |
|---|
| Gene | HYAL2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 473 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (177)
Diseases linked to this target (Open Targets).
- triatrial heart · score 0.50
- neurodegenerative disease · score 0.45
- cleft lip/palate · score 0.38
- genetic disorder · score 0.19
- body height · score 0.10
- cutaneous melanoma · score 0.10
- breast cancer · score 0.08
- malignant pleural mesothelioma · score 0.08
- bifid uvula · score 0.07
- cleft palate-lateral synechia syndrome · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q12891-F1 | alphafold | PREDICTED | 90.99 | — |
Amino-acid sequence (473 residues)
MRAGPGPTVT LALVLAVSWA MELKPTAPPI FTGRPFVVAW DVPTQDCGPR LKVPLDLNAF DVQASPNEGF VNQNITIFYR DRLGLYPRFD SAGRSVHGGV PQNVSLWAHR KMLQKRVEHY IRTQESAGLA VIDWEDWRPV WVRNWQDKDV YRRLSRQLVA SRHPDWPPDR IVKQAQYEFE FAAQQFMLET LRYVKAVRPR HLWGFYLFPD CYNHDYVQNW ESYTGRCPDV EVARNDQLAW LWAESTALFP SVYLDETLAS SRHGRNFVSF RVQEALRVAR THHANHALPV YVFTRPTYSR RLTGLSEMDL ISTIGESAAL GAAGVILWGD AGYTTSTETC QYLKDYLTRL LVPYVVNVSW ATQYCSRAQC HGHGRCVRRN PSASTFLHLS TNSFRLVPGH APGEPQLRPV GELSWADIDH LQTHFRCQCY LGWSGEQCQW DHRQAAGGAS EAWAGSHLTS LLALAALAFT WTL
Explore Hyaluronidase-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets